The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Open accessAbstract
Emergence of novel treatment modalities provides effective therapeutic options, apart from conventional cytotoxic chemotherapy, to fight against colorectal cancer. Unfortunately, drug resistance remains a huge challenge in clinics, leading to invariable occurrence of disease progression after treatment initiation. While novel drug development is unfavorable in terms of time frame and costs, drug repurposing is one of the promising strategies to combat resistance. This approach refers to the application of clinically available drugs to treat a different disease. With the well-established safety profile and optimal dosing of these approved drugs, their combination with current cancer therapy is suggested to provide an economical, safe and efficacious approach to overcome drug resistance and prolong patient survival. Here, we review both preclinical and clinical efficacy, as well as cellular mechanisms, of some extensively studied repurposed drugs, including non-steroidal anti-inflammatory drugs, statins, metformin, chloroquine, disulfiram, niclosamide, zoledronic acid and angiotensin receptor blockers. The three major treatment modalities in the management of colorectal cancer, namely classical cytotoxic chemotherapy, molecular targeted therapy and immunotherapy, are covered in this review.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, several existing drugs have been repurposed as potential anticancer agents, including some non-steroidal anti-inflammatory drugs (NSAIDs), statins (cholesterol lowering drugs), and metformin (anti-diabetic drug), which were shown to augment apoptosis and overcome chemoresistance in CRC cells [148].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [148]
In the citing paper
“Additionally, repurposed drugs like metformin and NSAIDs, as well as natural products such as curcumin, salvianolic acid, and vitamin C are being studied for their ability to target colorectal CSC self-renewal, proliferation, apoptosis, and ROS pathways and help overcome therapy resistance [148,210].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [148]
In the citing paper
“the repurposing of various clinically approved drugs, which were originally used to treat different diseases but also possess the ability to combat therapy resistance in CRC, can reduce the cost and time needed for drug development [148,242].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [148]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Research works printed but not linked: 1
- Du B, Guo Y, Jin L, Xiong M, Liu D, Xi X (2017) Targeting autophagy promote the 5-fluorouracil induced apoptosis in human colon cancer cells. Int J Clin Exp Pathol 10:6071–6081
Cited by
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“…several existing drugs have been repurposed as potential anticancer agents, including some non-steroidal anti-inflammatory drugs (NSAIDs), statins (cholesterol lowering drugs), and metformin (anti-diabetic drug), which were shown to augment apoptosis and overcome chemoresistance in CRC cells [148].”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Wang, K., Liu, W., Xu, Q., Gu, C., & Hu, D. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153553 · Cited by 28
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Metadata
- Authors
- Fong, W., & To, K. K. W.
- Affiliations
- Chinese University of Hong Kong (HK)
- Corresponding author
- To, Kenneth K. W.
- ORCID
- To, Kenneth K. W.
- Venue
- Cellular and Molecular Life Sciences
- Published
- 2019-05-13
- Volume
- 76
- Issue
- 17
- Pages
- 3383-3406
- ISSN
- 1420-682X (ISSN-L)
- 1420-9071
- PMC
- PMC11105507
- OpenAlex
- W2946262777
- Cited by
- 81
- References
- 134
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 10 · 2022: 12 · 2021: 17 · 2020: 8 · 2019: 10
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cellular and Molecular Life Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Health and Medical Research Fund (03140276)
- Medicine Panel of the Chinese University of Hong Kong (Direct Grant for Research 4054371)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- drug repurposing, colorectal cancer, drug resistance, nonsteroidal anti-inflammatory drugs, statins, metformin, chloroquine, disulfiram, niclosamide, zoledronic acid, angiotensin receptor blockers, cytotoxic chemotherapy, targeted therapy, immunotherapy
- MeSH terms
- Antineoplastic Agents, Immunological, Anti-Inflammatory Agents, Non-Steroidal, Antimetabolites, Antineoplastic Agents, Humans, Colorectal Neoplasms, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Drug Repositioning, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug repurposing to overcome resistance to various therapies for colorectal cancer. https://app.cochat.ai/papers/10.1007/s00018-019-03134-0
- The paper
- Fong, W., & To, K. K. W. (2019). Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-019-03134-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.